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ABSTRACT
Murine MC3T3-E1 and MC-4 cells were stably transfected with  371/þ70bp of the murine cyclooxygenase-2 (COX-2) promoter fused to
a luciferase reporter (Pluc371) or with Pluc371 carrying site-directed mutations. Mutations were made in (1) the cAMP response element
(CRE) at  57/ 52bp, (2) the activating protein-1 (AP-1)–binding site at  69/ 63bp, (3) the nuclear factor of activated T-cells (NFAT)–
binding site at  77/ 73bp, and (4) both the AP-1 and NFAT sites, which comprise a composite consensus sequence for NFAT/AP-1.
Single mutation of CRE, AP-1, or NFAT sites decreased parathyroid hormone (PTH)–stimulated COX-2 promoter activity 40% to 60%,
whereas joint mutation of NFAT and AP-1 abrogated the induction. On electrophoretic mobility shift analysis, PTH stimulated binding of
phosphorylated CREB to an oligonucleotide spanning the CRE and binding of NFATc1, c-Fos, and c-Jun to an oligonucleotide spanning
the NFAT/AP-1 composite site. Mutation of the NFAT site was less effective than mutation of the AP-1 site in competing binding to the
composite element, suggesting that cooperative interactions of NFATc1 and AP-1 are more dependent on NFAT than on AP-1. Both PTH
and forskolin, an activator of adenylyl cyclase, stimulated NFATc1 nuclear translocation. PTH- and forskolin-stimulated COX-2 promoter
activity was inhibited 56% to 80% by calcium chelation or calcineurin inhibitors and 60% to 98% by protein kinase A (PKA) inhibitors.
These results indicate an important role for the calcium-calcineurin-NFAT signaling pathway in the PTH induction of COX-2 and suggest
that cross-talk between the cAMP/PKA pathway and the calcium-calcineurin-NFAT pathway may play a role in other functions of PTH in
osteoblasts.  2010 American Society for Bone and Mineral Research.
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Introduction
P
rostaglandins (PGs), especially PGE2, are abundantly pro-
duced by osteoblasts and can stimulate both formation and
resorption of bone.
(1) Cyclooxygenase (COX) catalyzes the
committed step in the conversion of arachidonic acid, released
from membrane phospholipids, to PGs. Although there are two
kinds of COX, COX-1 and COX-2, the inducible enzyme, COX-2, is
responsible for most PGs produced by osteoblasts.
(1–3) Multiple
factors can induce the expression of COX-2 in osteoblasts,
including hormones, cytokines, and mechanical loading.
(1)
Parathyroid hormone (PTH) is a major physiologic regulator of
bone remodeling and calcium homeostasis. Although PTH
stimulates both bone resorption and formation, PTH injected
intermittently increases bone formation more than resorption.
Recombinant human PTH(1-34) is the only anabolic therapy
currently approved in the United States for treatment of
osteoporosis.
(4–6) PTH is a potent inducer of COX-2 in osteoblasts
via the cyclic adenosine monophosphate (cAMP) protein kinase
A (PKA) pathway.
(7–9) Because PTH and PGE2 can have similar
effects on bone remodeling, it is possible that some of the local
effects of PTH may be mediated via the induction of COX-2
expression and PGE2 production.
Nuclear factor of activated T-cells (NFAT) is a family of
transcription factors initially identified as regulating cytokine
and early immune-response gene expression in T cells
(10) and
now known to be important in regulating gene expression and
cell behavior in many nonimmune cells, including cardiomyo-
cytes,
(11) endothelial cells,
(12,13) and glomerular mesangial
cells.
(14)TherearefiveknownNFATmembers.NFAT5isregulated
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819by osmotic pressure. NFATc1 through NFATc4 are chiefly
activated by the calcium-calcineurin pathway. Inactive, phos-
phorylated NFATs (c1–4) are located in the cytoplasm. When
intracellular calcium ion concentration increases, calcineurin can
beactivatedanddephosphorylateNFATproteins,whichthenare
translocated into the nucleus and become functional.
(15) The
activity of NFAT proteins may be modulated by interaction with
transcription partners. NFAT proteins and AP-1 heterodimers
(Fos/Jun) can bind cooperatively to a composite DNA site
[GGA(N)9TCA] to activate gene expression.
(16) NFATc1 plays an
essential role in osteoclast differentiation,
(17,18) and NFATc1 and
NFATc2 are important in osteoblast differentiation.
(19,20)
NFAT regulates COX-2 expression in several cell types. NFAT
and AP-1 proteins were essential for increased COX-2 expression
in T-lymphocytes in response to phorbol 12-myristate 13-acetate
(PMA) and calcium ionophore.
(21) NFAT also was shown to
mediate the stimulation of COX-2 expression by vascular
endothelial growth factor (VEGF) in endothelial cells
(13) and by
endothelin-1 in glomerular mesangial cells.
(14)
In this study we show that PTH induces COX-2 transcription in
murine osteoblastic cells via both CRE- and NFAT/AP-1–binding
sites. This induction involves crosstalk between the cAMP-PKA
pathway,whichisthoughttomediatetheanaboliceffectsofPTH
in bone, and the calcium-calcineurin-NFAT signaling pathway.
Hence it is possible that some of the anabolic actions of PTH may
involve the NFAT pathway.
Materials and Methods
Materials
The promoterless luciferase vector, the DNA constructs consist-
ing of  371/þ70bp of the murine COX-2 gene (Pluc371), as well
as 50 deletions of the  371/þ70bp region, fused to a luciferase
reporter gene in pXp-2 vector, have been described pre-
viously.
(22–24) H-89, KT5720, and GF 109203X were purchased
from Biomol (Plymouth Meeting, PA, USA). The NFAT-selective
inhibitor VIVIT peptide was purchased from Calbiochem (San
Diego, CA, USA). The PKA agonist 6-Bnz-cAMP and the Epac
agonist 8-pCPT-2’-O-Me-cAMP were purchased from Biolog Life
Science Institute (San Diego, CA, USA). The retroviral vector
pMSCV-GFP and the pMSCV–constitutively active NFATc1
(caNFATc1)–GFP plasmid constructs were kind gifts of Dr Neil
A Clipstone (Loyola University). Synthetic bovine PTH (1-34),
forskolin, phorbol myristate acetate (PMA), and other chemicals
were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Cell culture
MC3T3-E1 cells, immortalized from neonatal murine calvariae,
were the kind gift of Dr Yoshiyuki Hakeda (Meikai University
School of Dentistry, Sakado, Saitama, Japan). The MC-4 cell line,
subcloned from MC3T3-E1 cells by Dr Franceschi at the
University of Michigan,
(25) was purchased from the American
Type Culture Collection (CRL-2593, ATCC, Manassas, VA, USA).
MC3T3-E1 cells were grown in phenol red–free Dulbecco’s
modified Eagle’s medium (DMEM, Sigma-Aldrich), and MC-4 cells
were grown in a modified Eagle’s medium (a-MEM, (Invitrogen,
Carlsbad, CA, USA). Both media contained 10% heat-inactivated
fetal calf serum (FCS, Gibco, BRL, Gaithersburg, MD, USA),
penicillin (100U/mL), and streptomycin (50mg/mL). Cells were
plated in 6 well dishes at 5000/cm
2 and grown until confluent in
ahumidifiedatmosphereof5%CO2at378C.MC3T3-E1cellswere
changed to serum-free medium with 1% BSA 24 hours before
treatment. Treatments were pulsed into MC-4 cultures without
changing the medium to avoid the COX-2 induction effects of
fresh serum. Inhibitors were pulsed 1 hour before treatment with
PTH or forskolin.
Stable transfection
Stable transfections of MC3T3-E1 or MC-4 cells were performed
as described previously.
(26) After selection, colonies (>200) were
pooled to minimize effects secondary to variable integration
sites. Cells were grown in culture medium containing 200mg/mL
of G418 (Invitrogen). To maintain uniform cell phenotype, all
constructs to be studied were transfected at the same time.
Passage number after transfection was restricted to less than 10.
Luciferase activity
Luciferaseactivitywasmeasuredinsolublecellextractsprepared
with a kit from Promega (Madison, WI, USA) using an automatic
injection luminometer (Berthold Lumat, Wallac, Inc., Oak
Ridge, TN, USA) For each experiment, 3 wells of a 6 well dish
of cells were analyzed per treatment group. Luciferase activity
was measured as relative light units per second (RLU/s) and
normalized to total protein measured with a bicinchoninic acid
(BCA) protein assay kit (Thermo Scientific, Rockford, IL, USA).
Using these normalized values, fold induction of luciferase
activity was calculated as the ratio of each sample to the mean
activity for the appropriate control group.
Site-directed mutation
The template sequence for all mutations was the murine  371/
þ70bp COX-2 DNA construct. The AP-1 sequence (5’-AGAGTCA-
3’)a t 69/ 63bp was changed to 5’-AGAGTtg-3’ (muAP-1)a s
described previously.
(26) The CRE (5’-CGTCA-3’)a t 56/ 52bp
was changed to 5’-atTCA-3’ (muCRE) as described pre-
viously.
(26,27) The NFAT sequence (5’-GGAAA-3’)a t 77/ 73bp
was changed to 5’-ttAAA-3’ (muNFAT) using the QuickChange
Site-Directed Mutagenesis Kit from Stratagene (La Jolla, CA, USA)
following the manufacturer’s directions. After introduction of
deletions or mutations, the COX-2 5’-flanking region was
sequenced (Automated DNA Sequence Facility, University of
Connecticut Health Center, Farmington, CT, USA). Mutated
oligonucleotides were used as unlabeled competitors on
electrophoretic mobility gel-shift assay (EMSA) to confirm that
binding to the mutated sequence did not occur.
Electrophoretic mobility gel-shift assay (EMSA)
Cells were washed with PBS and collected by centrifugation, and
nuclear extracts were obtained using a kit (BioVision Research
Prodicts, Mountain View, CA, USA). Single-stranded oligonucleo-
tides (Integrated DNA Technologies, Coralville, IA, USA)
were annealed with complementary oligonucleotides, and the
resulting double-stranded DNAs were end labeled with g
32P-ATP
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The 6mg of nuclear extract was incubated in 20mL binding-
reaction mixture [10mM Tris HCl, pH 7.5, 1mM DTT, 1mM EDTA,
5% glycerol, and 2mg poly dI-dC (Amersham Biosciences,
Piscataway, NJ, USA)] with 50,000 cpm of purified labeled probe.
Nondenaturing acrylamide gel (5%) electrophoresis was per-
formed for 2 hours. Competitors (50 to 300M excess) or
supershifting antibodies (4mg) were added to the binding
mixture 30 minutes before addition of the probe, and incubation
wascontinued for 30 minutes at 48C. Antibodies to NFATc1-c4, c-
Fos or c-Jun, and phosphorylated CREB were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Normal
mouse and rabbit IgGs were purchased from Millipore (Billerica,
MA, USA). Dried gels were exposed to X-ray film or phosphor
image plate.
Western blot analysis
Nuclearand cytosolic extracts were obtainedwith afractionation
kitfromBioVision.ProteinconcentrationsweremeasuredbyBCA
assay (Thermo Scientific). Equal amounts (25 or 40mg) of protein
were used for 10% SDS-PAGE and transferred to nitrocellulose
membrane (Bio-Rad Lab, Helcules, CA, USA). Membranes were
washed with Tris-buffered saline (TBS, pH 7.6), blocked with 5%
wt/vol nonfat dry milk in 1 TBS containing 0.05% Tween 20
(TBST) overnight at 48C, and incubated with primary antibody
(Santa Cruz) at 1:200 dilution. After washing with TBST,
membranes were incubated with horseradish peroxidase–
conjugated secondary antibody at 1:1,000 dilution. The signal
was detected with LumiGLO chemiluminescent reagent (Cell
Signaling Technology, Danvers, MA, USA).
Real-time (quantitative) PCR analysis
Gene expression studies were done using TaqMan fluorogenic
probes. Total RNA was extracted with Trizol (Invitrogen)
following the manufacturer’s instructions. Then 5mg of total
RNA was converted to cDNA using the high-capacity cDNA
Archive Kit (Applied Biosystems, Foster City, CA, USA) according
to the manufacturer’s directions. Real-time PCR for COX-2
expression was performed in 96 well plates using the Assays-on-
Demand gene expression system (Applied Biosystems) with
TaqMan fluorogenic probes and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) as the endogenous control. Each
sample was amplified in duplicate. The PCR reaction mixture
(20mL/well including 2 TaqMan Universal PCR Master Mix,
20 Assays-on-Demand Gene Expression assay mix, and 100ng
of cDNA) was run in the ABI Prism 7300 Sequence machine
universal thermal cycling parameters. The standard-curve
method was used for data analysis.
Chromatin immunoprecipitation (ChIP) assay
ChIP assay was performed using the EZ-CHIP Kit from Millipore
followingthemanufacturer’s instructions. MC-4cellsweregrown
to confluency, treated for 1 hour with PTH (10nM) or vehicle,
cross-linked with formaldehyde, lysed, sonicated with six sets of
20-second pulses, and soluble chromatin harvested. Supernat-
ant was precleared with protein G agarose and purified
by centrifugation. Immunoprecipitation was performed by
incubating the samples overnight at 48C with 2mg of mouse
NFATc1 antibody (Santa Cruz) or 1mg anti-RNA polymerase
antibody (positive control) or 1mg of mouse IgG antibody
(negative control), followed by incubation with protein G
agarose for 1 hour at 48C to collect antibody-antigen-DNA
complexes. Protein-DNA complexes were eluted from the
agarose and reverse cross-linked to free the DNA, which was
then purified using spin columns. The DNA solution also was
used as the template for SYBR Green quantitative polymerase
chain reaction (PCR). Specific primers encompassing the NFAT
binding sites on the COX-2 promoter (from nucleotide  135 to
 4bp) were designed using the NCBI/Primer-BLAST program
(www.ncbi.nlm.nih.gov/BLAST). Experimentally validated murine
primer pairs for actin (ID 6671509a1) were found in PrimerBank
(http://pga.mgh.harvard.edu/primerbank). Primers were made
by Integrated DNA Technologies. The PCR reaction mixture for
SYBR Green assays contained 2  SYBR Green PCR Master Mix
(Applied Biosystems) forward and reverse primer mix at final
concentration for each primer of 200nM and 2mL of DNA
solution. The reaction was run in triplicate for each sample under
a common PCR thermal profile: 508C for 2 minutes, 958C for 10
minutes, 958C for 15 seconds, 608C for 30 seconds, and 728C for
30 seconds. PCR products were analyzed by gel electrophoresis
(37 cycles) and by real-time PCR(40 cycles). For real-time PCR, we
started with equal amounts of chromatin for each sample, and
the Ct values for each sample were calculated without normal-
ization. The ChIP assay was done in duplicate.
Statistical analysis
Meansofgroupswerecomparedbyone-wayanalysisofvariance
(ANOVA) using SigmaStat for Windows, Version 2.03 (San Rafael,
CA,USA).Significance ofdifferenceswasdeterminedbypost hoc
testing using Bonferonni t test or the Tukey test.
Results
Site-directed mutation of CRE, AP-1, and NFAT elements
Studies were done in both preosteoblastic MC3T3-E1 cells and
MC-4 cells. MC-4 cells were subcloned from MC3T3-E1 cells
because of concerns that MC3T3-E1 cells had become a mixed
population of phenotypes after years of being carried by various
laboratories and were shown to have high differentiation and
mineralization potential.
(25) All studies were done in stably
transfectedcellsgrownfor6to7daysafterplating.PTHhasbeen
showntorapidlyinducetranscription andexpressionofCOX-2in
MC3T3-E1 cells.
(8,9) In both MC3T3-E1 and MC-4 cells stably
transfected with Pluc371, PTH-stimulated luciferase activity
peaked at 2 to 3 hours and returned to baseline by 8 hours
(Fig.1A,B).Weusedthe3hourtimepointforallfurtherstudiesof
luciferase activity.
We made mutations in the cAMP response element (CRE) that
is important for the regulation of COX-2 expression by multiple
agents,
(27) an AP-1-binding site that partially mediates effects of
PMA and serum on COX-2,
(2) and an NFAT consensus
sequence
(21) (see Fig. 1C). The sequence 50-GGAAAGACA-
GAGTCA-3 spanning the NFAT and AP-1 sites is identical to an
NFAT/AP-1 composite consensus sequence GGA(N)9TCA
(12) and
PTH INDUCTION OF COX-2 VIA NFAT/AP-1 Journal of Bone and Mineral Research 821Fig. 1. Induction of murine COX-2 promoter activity by PTH in MC3T3-E1 and MC-4 cells is dependent on the CRE, AP-1, and NFAT sites. Cells stably
transfected with wild-type (WT) Pluc371 or Pluc371 with 2bp mutations in the CRE, AP-1, and NFAT sites were treated with vehicle or PTH (10nM). Unless
otherwisespecified,cellsweretreatedfor3hours.Luciferaseactivitywascalculatedasrelativelightunits(RLU)/sandnormalizedtototalprotein.Usingthe
normalized values, fold induction of luciferase activity was calculated as the ratio of each sample activity to the mean activity for the appropriate control
group. Time course for the PTH induction of COX-2 promoter luciferase reporter activity in (A) MC3T3-E1 cells and in (B) MC-4 cells carrying Pluc371. (C)
Locationin themurineCOX-250-flankingregionofthemutatedcis-actingelements.(D) Comparisonofnucleotidesequencesin the 80/ 60bpCOX-25’-
flanking regions of the human, rat and mouse genes. (E) Effects of mutating the CRE, AP-1, or both CRE and AP-1 sites in MC3T3-E1 cells on basal luciferase
activity and ( F) PTH-stimulated fold increase in luciferase activity. (G) Effects of mutating the AP-1, NFAT, or both AP-1 and NFAT sites in MC3T3-E1 cells on
basalluciferaseactivity,and(H)PTH-stimulatedfoldincreaseinluciferaseactivity.(I)EffectsofmutatingtheCRE,AP-1,andNFATsitesinMC-4cellsonbasal
luciferase activity, and (J) PTH-stimulated fold increase in luciferase activity. Bars or symbols are means SEM for n¼3 wells of cells.
aSignificant effect of
PTH, p<.01.
bSignificantly different from WT, p<.01.
cp<.05.
dSignificantly different from all other mutations, p<.01.
eSignificantly different from the
single NFAT mutation, p<.05.
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sequences
(21) (see Fig. 1D). NFAT and AP-1 (Fos/Jun) proteins
have been shown to interact cooperatively to mediate
transcription.
(12,28,29) We compared mutated constructs only in
cells transfected simultaneously with those constructs.
Mutations of the CRE, the AP-1 site, and both sites were
compared in MC3T3-E1 cells. A representative experiment is
shown in Fig. 1E, F. PTH (10nM) significantly induced luciferase
activity 7.2-fold in one experiment (see Fig. 1F) and 3.3- and 5.3-
fold in two other experiments (data not shown). AP-1 and CRE
mutations significantly decreased the PTH-stimulated fold
activity on average 60% and 50%, respectively. There was no
additional reduction in the response to PTH with the combina-
tion of AP-1 and CRE mutations in any of the three experiments.
Although the basal activity was variable among experiments, the
jointAP-1andCREmutationconsistentlyreducedbasalluciferase
activity (on average 76%) more than the individual mutations
(40% to 46%).
Mutations of the AP-1 site, the NFAT site, and both sites also
were compared in MC3T3-E1 cells. A representative experiment
isshowninFig.1G,H.PTHsignificantlyinducedluciferaseactivity
5.6-fold (see Fig. 1H) in one experiment and 3.8- and 8.9-fold in
the other two experiments (data not shown). Single mutation of
the AP-1 site significantly reduced the PTH stimulated fold
induction in two of the three experiments by 39%. Single
mutationoftheNFATsitesignificantlyreducedthefoldinduction
of PTH in all three experiments by 18% to 40%. In contrast, the
PTH-stimulated fold increase was decreased 82%, 94%, and 96%
by the joint AP-1 and NFAT mutations. The mutations produced
no consistent differences in basal activity.
Mutations of the CRE, the AP-1 site, the NFAT site, and both
the AP-1 and NFAT sites were compared in MC-4 cells. A
representative experiment is shown in Fig. 1I, J. In this
experiment, PTH induced a 10-fold increase in luciferase activity
that was reduced 61%, 54%, 64%, and 93% by the CRE, AP-1,
NFAT, and joint AP-1 and NFAT mutations, respectively. In a
second experiment, PTH induced a 5.8-fold increase in luciferase
activity that was significantly reduced 50%, 48%, 38%, and 98%,
respectively, by the CRE, AP-1, NFAT, and joint AP-1 and NFAT
mutations, respectively (data not shown). In a third experiment,
PTH induced a 7-fold increase in luciferase activity that was
significantly reduced 48%, 50%, and 94% by the AP-1, NFAT, and
combined mutations, respectively (data not shown).
In the six independent experiments in MC3T3-E1 and MC-4
cells, there was no statistically significant induction of luciferase
activity by PTH in any group with joint AP-1 and NFAT mutations,
suggestingthat the composite NFAT/AP-1 elementplays acritical
role in the PTH induction of COX-2 promoter activity. As noted
earlier, basal activity was quite variable even in repeated assays
on cells carrying the same construct, suggesting that despite
pooling of multiple clones for the transfection, some phenotypic
differences occurred during the selection process or during
passage. The joint NFAT/AP-1 mutation increased basal activity
significantly in three experiments, reduced basal activity
significantly in two experiments, and had no effect on basal
activity in the remaining experiment. Hence the abrogation of
PTH-stimulated luciferase activity by the combined AP-1 and
NFAT mutations was independent of effects on basal activity.
Binding of nuclear proteins to CRE, AP-1, and NFAT
elements
We performed EMSA on MC-4 cells treated with vehicle or PTH
(10nM) for 1 hour. There was constitutive binding of a
32P-labeled
COX-2 oligonucleotide ( 63/ 39bp) spanning the CRE site on
EMSA(Fig.2A,bandainlanes2,3,8,and9),withincreasedbinding
seen on some gels after PTH treatment. This binding was
competed by unlabeled oligonucleotide (lanes 4 and 5) but not by
unlabeled oligonucleotide with mutation of the CRE (MUT; lanes 6
and 7). Antibody to phosphorylated CREB (pCREB) supershifted a
band (lane 11, band b) in PTH-treated nuclear extracts but not in
vehicle-treated samples (lane 10). No supershift was observed in
extracts incubated with nonspecific IgG (lanes 12 and 13).
PTH induced binding of a
32P-labeled oligonucleotide ( 85 to
 57bp) that spanned the NFAT and AP-1 composite site (see
Fig. 2B, lane 3, band a). This binding was competed by unlabeled
oligonucleotide (lanes 4 and 5) but not by unlabeled
oligonucleotide with mutations in both AP-1 and NFAT sites
(lanes 6 and 7). Antibody to NFATc1 supershifted a band in PTH-
treated extracts (lane 11, band b). In contrast, antibodies to
NFATc2 (lanes 12 and 13), NFATc3 (lanes 14 and 15), and NFATc4
(lanes 16 and 17) did not alter the position of this band.
Antibodies to c-Fos and c-Jun also gave rise to retarded bands
(lanes 21 and 23, respectively). No supershifted band was seen
withIgG(lane19). Similarresults wereseenwithEMSA inMC3T3-
E1 cells (data not shown).
To demonstrate binding of NFATc1 to native chromatin in MC-
4 cells, we performed ChIP using primers spanning  135/ 4bp
of the COX-2 promoter region. PCR products run on agarose gel
and stained with ethidium bromide are shown in Fig. 2C.
Products also were analyzed by real-time PCR. The difference in
Ct values between control and PTH-treated samples was 4.8 in
one experiment and 3.9 in a second experiment, indicating an
increase in PTH-stimulated NFATc1 binding of about 20-fold. We
cannot rule out binding to several other potential NFAT elements
in the  135/ 4bp promoter sequence, which spans two
additional GGAAA sequences at  90/ 86 and  111/ 107bp.
However, mutation of either of these sites in combination with
mutation of the AP-1 site studied in stably transfected MC-4 cells
resulted in no greater decrease in PTH-stimulated luciferase
activity than the AP-1 mutation alone (data not shown).
TostudythecooperativebindingofNFATandAP-1proteinsto
the composite NFAT/AP-1 element, we compared the ability of
oligonucleotides carrying the single AP-1 mutation (muAP-1)o r
NFAT mutation (muNFAT) to compete the binding of nuclear
proteins to the NFAT/AP-1 element, as described previously
(29)
(Fig. 3). Unlabeled oligonucleotide with muAP-1 (lanes 16 to 18)
was almost as effective as the wild-type oligonucleotide (lanes 4
to 6) at competing for the formation of the protein-DNA
complexes and much more effective than the oligonucleotide
with muNFAT (lanes 22 to 24). These observations suggest that
interactions at the composite NFAT/AP-1 element are more
dependent on NFAT than on AP-1.
Involvement of the cAMP-PKA pathway
PTH exerts its effect on bone metabolism by binding to the G
protein–coupled PTH/PTH-related peptide receptor.
(30,31) PTH
PTH INDUCTION OF COX-2 VIA NFAT/AP-1 Journal of Bone and Mineral Research 823Fig. 2. PTH induces binding of nuclear proteins to the CRE, NFAT, and AP-1 elements. EMSA and ChIP analyses were performed on MC-4 cells treated with
PTH (10nM) for 1 hour. (A) Binding of nuclear proteins extracted from MC-4 cells to a
32P-labeled COX-2 oligonucleotide ( 63/ 39bp) spanning the CRE
( 57/ 52bp).Binding(arrowa, lanes2,3, 8,and9)was competed by unlabeled wild-type(WT)oligonucleotide (lanes4 and5) butnotby oligonucleotide
with 2bp mutationof the CRE (lanes 6 and 7) and supershifed by antibody to phoshorylated CREB (pCREB) (arrow b, lane 11) but not by IgG (lane 13). Lane
1: Free probe. (B) Binding of nuclear proteins extracted from MC-4 cells to a
32P-labeled COX-2 oligonucleotide ( 85/ 57bp) spanning the composite
NFAT/AP-1element( 77/ 63bp).PTH-inducedbinding(arrowa,lanes2and3)wascompetedbyunlabeledWToligonucleotide(lanes4and5)butnotby
oligonucleotide with mutation of the AP-1 and NFAT sites (lanes 6 and 7). Supershift was seen with antibody to NFATc1 (arrow b, lane 11) but not with
antibodiestoNFATc2–4orIgG(lanes13,15,17,and19).Supershiftalsowasseenwithantibodiestoc-Fos(arrowc,lane21)andc-Jun(lane23).Lane1:Free
probe. (C) ChIP assay for binding of NFATc1 to the native COX-2 promoter. Soluble chromatin extracts from MC-4 cells treated with vehicle or PTH were
incubated with anti-NFATc1 antibody, nonimmune IgG, or no antibody (input). Immunoprecipitated DNA was analyzed by PCR using primers spanning
 135/ 4bp of the COX-2 promoter region. PCR products were run on 2% agarose gel and stained with ethidium bromide.
Fig. 3. MutatingtheNFATelementhasagreatereffectonnuclearproteinbindingtothecomposite NFAT/AP-1sequencethanmutating theAP-1element.
EMSA was performed on nuclear extracts from MC-4 cells treated with PTH (10nM) for 1 hour using a
32P-labeled COX-2 oligonucleotide ( 85/ 57bp)
spanning the composite NFAT/AP-1 element ( 77/ 63bp). Unlabeled wild-type oligonucleotide (WT, lanes 4 to 6) or unlabeled oligonucleotide with
mutations in both AP-1 and NFAT (lanes 10 to 12), mutations in AP-1 only (muAP-1, lanes 16 to 18) or NFAT only (muNFAT, lanes 22 to 24) were used at 50,
100, and 300M excess. Lanes 1, 7, 13, and 19: Free probe.
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Gas protein, thereby increasing cAMP and activating PKA.
Although PTH is thought to mediate most of its biologic effects
in osteoblastic cells via cAMP-PKA signaling, PTH also can
activate the protein kinase C (PKC) pathway.
(32,33) H-89, a PKA
inhibitor, inhibits PTH induction of COX-2 transcription and
COX-2 mRNA and protein expression in MC3T3-E1 cells.
(8,9)
However, H-89 also strongly inhibits the induction of COX-2 by
PMA, a PKC agonist.
(34–36) To rule out involvement of the PKC
pathway, we examined effects of a specific PKC inhibitor GF
109203X on the induction of luciferase activity in MC-4 cells in
response to PMA (1mM) and forskolin (1mM), an adenylate
cyclase agonist. As reported previously,
(34–36) GF 109203X
inhibited the PMA induction (2.6-fold) of luciferase activity by
80%(data notshown),withnoeffect ontheforskolininduction
(7.1-fold) of luciferase activity (data not shown). GF 109203X
had no effect on the PTH induction of luciferase activity
(Fig. 4A). Consistent with earlier studies, H-89 abrogated the
PTH induction of luciferase activity (Fig. 4B). A more specific
PKA inhibitor, KT 5720,
(37) significantly inhibited the forskolin
induction (7.9-fold) of luciferase activity by 64% (data not
shown) and the PTH induction of luciferase by 60% (see
Fig. 4B).
Similar to the effects seen with PTH, the forskolin induction of
luciferase activity in stably transfected MC-4 cells was inhibited
50% to 60% by mutation of the AP-1 or NFAT site and abrogated
by joint mutation of these two sites (see Fig. 4C). On EMSA,
forskolin treatment induced binding (band a in lane 3) that was
supershifted by antibody to NFATc1 (band b in lane 5) but not by
antibodies to other members of the NFAT family (see Fig. 4D).
Exchange protein directly activated by cAMP (Epac) is another
targetofcAMPthatmediateseffectsofcAMPindependentofthe
PKA pathway. Epac is expressed in MC-4 cells and was shown to
mediate effects of PTH on cell proliferation.
(38) We compared
treatment with high doses (1mM) of the specific PKA agonist 6-
Bnz-cAMP and the specific Epac agonist 8-pCPT-20-O-Me-cAMP
on COX-2 mRNA expression in MC-4 cells.
(39) 6-Bnz-cAMP
induced COX-2 mRNA more than 8-fold, similar to induction
byPTHorforskolin,whereas8-pCPT-20-O-Me-cAMPhadnoeffect
on COX-2 message (see Fig. 4E).
Regulation of calcium-calcineurin-NFAT signaling by the
cAMP-PKA pathway
Increased concentration of intracellular calcium activates
calcineurin, and calcineurin activates NFATc1 protein in the
Fig. 4. PTH induction of COX-2 promoter activity depends on the cAMP-PKA pathway. (A, B) Effects of the specific PKC inhibitor GF109203X (0.6mM) and
the PKA inhibitors H-89 (30mM) and KT 5720 (10mM) on the luciferase activity or fold induction in response to PTH. MC-4 cells stably transfected with
Pluc371weretreatedwithvehicle,PTH,orforskolin(FSK).Inhibitorsorvehicle(Control)wereadded1hourbeforePTH.(C)EffectsofmutatingtheAP-1site,
the NFAT site, and both on the response to forskolin. MC-4 cells stably transfected with wild-type (WT) Pluc371 or Pluc371 with mutations in the AP-1 and
NFAT sites were treated for 3 hours with vehicle or forskolin (FSK). Luciferase activity was calculated as relative light units (RLU)/s and normalized to total
protein.Usingthenormalizedvalues,foldinductionofluciferaseactivitywascalculatedastheratioofeachsampletothemeanactivityfortheappropriate
control group. Bars are means SEM for n¼3 replicates.
aSignificant effect of PTH or forskolin, p<.01.
bSignificant effect of inhibitor or mutation, p<.01.
(D) EMSA of forskolin-induced nuclear binding to a
32P-labeled COX-2 oligonucleotide ( 85/ 57bp) spanning the composite NFAT/AP-1 element ( 77/
 63bp). MC-4cells weretreated with forskolin(FSK, 1mM) for 1 hour. Forskolin-inducedbinding(arrowa, lane3) was supershifted by antibody to NFATc1
(arrow b, lane 5) but not by antibodies to NFATc2–4 (lanes 7, 9, and 11) or IgG (lane 13). Lane 1: Free probe. (E) Effects of specific PKA and Epac agonists on
COX-2mRNAexpression,measuredbyreal-timeRT-PCR.MC-4cellsweretreatedwithvehicle(VEH),PTH(10nM),forskolin(FSK,1mM),6-Bnz-cAMP(1mM),
and 8-pCPT-20-O-Me-cAMP (1mM) for 1 hour. Bars are means SEM for n¼3 replicates.
aSignificant effect of agonist, p<.01.
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(15) Dephosphorylated NFAT1c
translocates to the nucleus. Consequently, cellular localization of
NFAT1c is an indication of its activation status. We examined by
Western blot the distribution of NFAT proteins in the cytoplasm
and nucleus in MC-4 cells treated with vehicle or PTH. Nuclear
concentration of NFATc1 was increased by PTH (Fig. 5A).
Forskolin also stimulated nuclear translocation of NFATc1, but
PMA did not (Fig. 5B).
PTH-stimulated COX-2 mRNA expression in MC-4 cells was
inhibited inhibited 88% by the calcium chelator BAPTA-AM and
58% and 65%, respectively, by the calcineurin inhibitors FK506
and cyclosporin A (CsA) (Fig. 6A). PTH-stimulated Pluc371
activity in MC-4 cells was inhibited 99% by BAPTA-AM and
56% to 60% by the calcineurin inhibitors FK506, CsA, and VIVIT
in the experiment shown in Fig. 6B. In a second experiment,
PTH-stimulated Pluc371activitywasinhibited81%byBAPTA-AM
and 76% to 81% by FK506 and CsA (p<.01; data not shown).
Forskolin-stimulated Pluc371 activity was inhibited 76% by
BAPTA-AMand64%to65%byFK506andCsA(seeFig.6C).These
data indicate that PTH can stimulate COX-2 mRNA and promoter
activity via crosstalk between the cAMP-PKA and calcineurin-
NFAT signaling pathways.
Enhancement of COX-2 mRNA expression by NFATc1
overexpression
We stably transfected MC-4 cells with a constitutively active
mutant form of NFATc1 (caNFATc1) or its control vector (pMSCV-
GFP).
(40) Nuclear expression of NFATc1 protein was increased in
cells stably transfected with caNFATc1 compared with control
Fig. 5. NFATc1 nuclear translocation is induced by PTH and forskolin but not by PMA in MC-4 cells. MC-4 cells were treated for 30 to 60 minutes.
Factionated nuclear and cytoplasmic proteins were extracted as described in ‘‘Materials and Methods.’’ (A) NFATc1 nuclear translocation induced by
treatment with PTH (10nM). (B) NFATc1 nuclear translocation induced by 1 hour of treatment with vehicle (VEH), forskolin (FSK, 1mM), or PMA (1mM).
b-actin and histone H1 are shown to assess loading on gel.
Fig. 6. PTH induction of COX-2 expression and promoter activity depends on calcium-calcineurin signaling. MC-4 cells stably transfected with Pluc371
weretreated withvehicle,PTH(10nM), orforskolin (FSK,1mM) for1 hour(mRNA)or3 hours (luciferaseactivity).BAPTA-AM(BAPTA,15mM),FK506 (10mg/
mL), cyclosporin A (CsA, 10mg/mL), or VIVIT (1mM) were added 1 hour before PTH or forskolin. Vehicle (CON) for the inhibitors, DMSO, also was added
1 hour before PTH or forskolin. Luciferase activity was normalized to total protein and used to calculate the fold induction as the ratio of treatment to
control. (A) Effects of the calcium chelator BAPTA-AM and the calcineurin inhibitors FK506 and CsA on PTH-induced COX-2 mRNA expression measured by
real-timeRT-PCR.(B)EffectofBAPTA-AMandthecalcineurininhibitorsFK506,CsA,andVIVITonthePTHinductionofluciferaseactivity.(C)EffectofBAPTA-
AM, FK506, and CsA on the forskolin induction of luciferase activity. Bars are means SEM for n¼3 wells of cells.
aSignificant effect of agonist, p<.01.
bSignificant effect of inhibitor, p<.01.
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was increased 3.3- and 1.6-fold, respectively, in the caNFATc1
expressing cells compared with control cells (Fig. 7B).
Discussion
Our results are consistent with earlier studies that reported the
PTH induction of COX-2 expression and promoter activity to be
mediated via the cAMP-PKA pathway.
(8,9) As expected, the CRE,
which is involved in the induction of COX-2 promoter activity by
multiplefactors,
(26,27,41) wasfound to playasignificant role inthe
PTH induction of COX-2 promoter activity. PTH increased binding
of phosphorylated CREB-1 to the CRE on EMSA, and a 2-bp
mutation in the CRE reduced PTH-stimulated COX-2 promoter-
luciferase activity 50% to 60%.
Transcriptional regulation of COX-2 by most factors appears to
involve multiple cis-acting sites.
(1,42) Along with the CRE, the AP-
1-binding element at  69/ 63bp has been shown to mediate
inductionofCOX-2byserumandPMA.
(26)PTHinducedc-Fos and
c-Jun binding to the oligonucleotide spanning the AP-1-binding
site on EMSA, and a 2-bp mutation of this AP-1 element reduced
PTH-stimulated luciferase activity 40% to 60%. A role for AP-1
factors in mediating PTH effects has been found in several
other systems. For example, PTH can induce collagenase
expression
(43,44) and c-Fos expression
(45) via AP-1 factors.
The reduction in PTH stimulated COX-2 promoter activity by a
2bp mutation of the NFAT element alone ranged from 18% to
64%. The joint mutation of the AP-1 and NFAT elements, which
form a consensus NFAT/AP-1 composite binding sequence,
consistently abrogated the PTH induction of COX-2 promoter
activity. EMSA showed that PTH stimulated NFATc1 but not
NFATc2–4 binding to a sequence spanning the composite site
andthatNFATplayedadominantroleinthecooperativebinding
ofNFATandAP-1proteinstothecompositesite.BindingofNFAT
and AP-1 proteins to a composite NFAT/AP-1 site is reported to
be important in the regulation of expression of cytokine and
surface receptor genes in immunocytes
(16,46) and in the
induction of COX-2 by PMA and calcium ionophore in human
T-lymphocytes
(21) and by HIV-Tat in glial cells.
(47) Our data
indicate that this composite NFAT/AP-1 elementis also important
for COX-2 induction by PTH in osteoblasts and that constitutively
active NFATc1 can enhance the basal and PTH-stimulated
expression of COX-2 in osteoblast cultures.
Although regulation of NFAT activity has been shown to be
involved in mediating COX-2 transcription by a variety of
agents,
(13,14,21,47,48) this is the first study to report regulation by
an agent thought to act largely via the cAMP-PKA pathway.
Previous studies on the relationship between the cAMP-PKA
pathway and the calcium-calcineurin-NFAT pathway have
reported differing results. PKA had inhibitory effects on NFAT
activity in T-lymphocytes and mouse lymphoma EL-4 cells
(49–51)
butactivated NFATproteinsinpancreatic isletbcells.
(52,53) Inthis
study, the adenylate cyclase agonist forskolin mimicked the
effects of PTH, stimulating binding of nuclear proteins to the
NFAT/AP-1 composite element and activating NFATc1 nuclear
translocation. Inhibitors of PKA inhibited the stimulation of COX-
2 promoter activity by PTH and forskolin similarly. Calcium
chelation as well as calcineurin inhibitors significantly blunted
effectsofbothPTHandforskolinonCOX-2promoteractivity.PTH
has been shown to activate ERK phosphorylation via Epac in MC-
4 cells.
(38) Although we cannot rule out a role for Epac, our data
strongly suggest that PTH activates the calcium-calcineurin-
NFAT pathway via cAMP-PKA signaling.
One possible mechanism for the association of cAMP-PKA and
calcium-calcineurin activity in osteoblasts might be the family of
scaffold proteins called A kinase-anchoring proteins (AKAPs). In a
variety of cells, including T-lymphocyte, adipocytes, cardiomyo-
cytes, and myocytes, PKA can form a signal-transduction
complex with AKAPs located in different subcellular compart-
ments through interactions with lipids or other proteins.
(54) Our
preliminary studies show expression of AKAP79 and AKAP18
proteins in MC-4 cells (data not shown). Some studies report that
calcineurin can be a part of the AKAP complex and that PKA
activated by cAMP can sensitize calcium channels on the cell
compartment membrane, increasing the concentration of
calcium ions in the cytosol, which, in turn, activates calcineurin
and NFAT proteins.
(55–57)
Although NFAT proteins were identified originally as control-
ling cytokine and early immune-response gene expression in T
cells,
(10) they are now found to regulate gene expression in a
variety of cells.
(11–14) NFATc1 plays a pivotal role in osteoclast
differentiation.
(17,18) NFAT proteins are also likely tobe important
in osteoblast differentiation and function. Although one study
showed that overexpression of NFATc1 in vitro inhibited
osteoblast differentiation,
(58) other studies have shown that
NFATc1 deficiency suppressed osteoblast differentiation in
vitro
(19); NFATc1 or NFATc2 deficiency caused a defect in bone
formation in vivo
(19,20); and NFATc1 overexpression in vivo
resulted in increased osteoblast proliferation and high bone
mass.
(20)
PTH stimulates bone formation and resorption by acting on
cells of the osteoblastic lineage to increase both their
differentiation into mature matrix-producing cells and their
essentialsupportforthedifferentiationofosteoclasts. Theresults
of our study show that PTH can activate the calcium-calcineurin-
NFAT signaling pathway and that this activation is important for
Fig. 7. NFATc1 overexpression enhances basal COX-2 expression and
induction by PTH. MC-4 cells stably transfected with pMSCV-GFP (vector)
orpMSCV-caNFATc1-GFPplasmidconstructsweretreatedwithvehicleor
PTH (10nM) for 1 hour. (A) Nuclear protein extraction and Western blot
were performed as described in ‘‘Materials and Methods.’’ (B) COX-2
mRNA levels measured by real-time RT-PCR. Bars are means SEM for
n¼3wells ofcells.
aSignificant effectofPTH, p<.01.
bSignificant effectof
caNFATc1 overexpression, p<.01.
PTH INDUCTION OF COX-2 VIA NFAT/AP-1 Journal of Bone and Mineral Research 827the PTH induction of COX-2 expression in osteoblasts. These
results suggest that crosstalk between the cAMP/PKA pathway
and the calcium-calcineurin-NFAT pathway may play a role in
other functions of PTH that are important for the regulation of
bone turnover.
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